Please login to the form below

Not currently logged in
Email:
Password:

Mundipharma appoints Dr Alberto Martinez as president and CEO

He succeeds Antony Mattessich, who leaves after 12 years with the networked company

Alberto MartinezMundipharma has appointed Dr Alberto Martinez as its new president and chief executive officer, succeeding Antony Mattessich, who leaves the network after 12 years of service to pursue his career in the US.

Dr Martinez’ career has seen him gain expertise in the healthcare and pharmaceutical fields, more specifically in the strategic, financial and operational capacity.

His new role will see him take responsibility for strengthening Mundipharma’s network in Europe and focus on its alliances.

Additionally, research and development, global manufacturing, supply chain and IT functions will fall under Dr Martinez’s new remit.

He said: “I feel honoured and privileged to be given the opportunity to lead the Mundipharma organisations in Europe in the next chapter of our evolution and success. I am committed to ensure that we remain ambitious and agile so we continue to bring valuable and innovative medicines to patients and healthcare providers as a successful, diversified and forward-thinking organisation.”

Dr Martinez originally joined the Mundipharma network in 2003 and has held roles of increasing responsibility over the past 14 years.

Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.

8th January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...